Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
To determine the time to progression produced by the combination of Novantrone (mitoxantrone)
and Erbitux (cetuximab) versus Novantrone alone in metastatic AIPC patients previously
treated with docetaxel-based chemotherapy. TTP is defined as time from the start of treatment
date to the date the patient is first recorded as having disease progression, even in
patients who discontinue study treatment early due to toxicity.
Phase:
Phase 2
Details
Lead Sponsor:
US Oncology Research
Collaborators:
Eli Lilly and Company ImClone LLC Oregon Health and Science University